Therapixel

Therapixel develops artificial intelligence software for medical imaging, focused on breast cancer screening. Its MammoScreen product analyzes 2D mammograms and 3D tomosynthesis images, scores each exam for suspicion of malignancy and marks the regions that deserve attention, so radiologists can read faster and with more confidence. The software is cleared by the FDA in the United States and CE marked in Europe, and it is used by radiology practices, hospitals and screening networks. The company was created by researchers from INRIA, keeps its research team in Paris and its software development in Nice, and concentrates entirely on radiology after selling its former surgical imaging business.